Zomedica, Celsee Inc. partner to deliver cancer liquid biopsy platformDecember 21, 2017Zomedica Pharmaceuticals Corp. has entered into a license and supply agreement with Celsee Inc., an innovator of progressive rare cell capture, characterization, and retrieval products in the emerging field of liquid biopsy. Under the terms of the agreement, Zomedica will have animal health exclusive global rights to develop and market Celsee's liquid biopsy platform for use by veterinarians as a cancer diagnostic. A liquid biopsy is a blood test with the potential to detect the presence of circulating tumor cells in the blood. Circulating tumor cells (CTC) are shed from a primary tumor into neighboring blood vessels and are transported throughout the body's circulatory system. The detection of CTCs in the blood could indicate a cancer diagnosis without the need for an invasive tissue biopsy, according to Zomedica. "Liquid biopsy is cutting-edge technology in human medicine right now and we're excited about the opportunity to develop and market this platform for use in veterinary medicine," stated Gerald Solensky, Jr., CEO at Zomedica. "We selected the Celsee platform because of the ease of use, workflow simplicity, and flexibility to use our novel canine biomarkers. If we successfully develop Celsee's technology, we believe we will be able to …
SPONSORED CONTENTYour Parasite Protection Recommendation, SimplifiedManaging parasite prevention doesn’t have to be complicated. Discover a single solution that protects against multiple threats. + Learn More
